Preclinical evidence for anaplastic lymphoma kinase inhibitors as novel therapeutic treatments for cholangiocarcinoma

Preclinical evidence for anaplastic lymphoma kinase inhibitors as novel therapeutic treatments for cholangiocarcinoma

IntroductionBile duct cancer (cholangiocarcinoma, CCA) has a poor prognosis for patients, and despite recent advances in targeted therapies for other cancer types, it is still treated with standard chemotherapy. Anaplastic lymphoma kinase (ALK) has been shown to be a primary driver of disease progre...

Full description

Bibliographic Details
Main Authors: Kyaw Zwar Myint, Mireia Sueca-Comes, Pamela Collier, Brinda Balasubramanian, Simran Venkatraman, John Gordan, Abed M. Zaitoun, Abhik Mukherjee, Arvind Arora, Noppadol Larbcharoensub, Chinnawut Suriyonplengsaeng, Kanokpan Wongprasert, Tavan Janvilisri, Dhanny Gomez, Anna M. Grabowska, Rutaiwan Tohtong, David O. Bates, Kiren Yacqub-Usman
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-12-01
Series:Frontiers in Oncology
Subjects:
cholangiocarcinoma
Opisthorchis viverrini
anaplastic lymphoma kinase 1
novel therapeutics
cytotoxicity and autophagy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1184900/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1184900/full

Similar Items